Vir Biotechnology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
State Street Corporation has disclosed beneficial ownership of 5.9% of Vir Biotechnology Inc.'s common stock as of June 30, 2026.
NASDAQ
Vanguard Portfolio Management has reported a beneficial ownership of 6.85% in Vir Biotechnology Inc. common stock as of June 30, 2026.
NASDAQ
SoftBank Vision Fund entities have reported a 6.5% beneficial ownership stake in Vir Biotechnology, Inc. as of March 31, 2026.
NASDAQ
Vanguard Portfolio Management has reported beneficial ownership of 5.79% of Vir Biotechnology Inc.'s common stock as of March 31, 2026.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Vir Biotechnology Inc. following an internal realignment.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 10.8% Passive Stake in Vir Biotechnology
BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 10.8% in Vir Biotechnology, Inc.'s common stock as of March 31, 2025.